But based on past practice they very well may. That is what much of the fuss was about on mammograms. If a particular procedure or test is not approved it is pretty common for insurance companies to then decide not to pay for that item. That reduces the number of people taking the test and, in turn, revenue to the company's producing the test material. Then the company's profit goals may not be met and production canceled.

Another consequence is that the test will continue to be marketed by the manufacturer but people won't be able to afford the price; even the $100 you mention.

Nope, I'd much prefer emphasis be placed on better analysis of test results rather than what appears to be current practice of automatically jumping to intrusive follow on procedures even though those are more profitable to the medical providers.